Pathological Mechanism-Inspired Biomimetic Nano-Senotherapy for Reversing Experimental Atherosclerosis in ApoEMice.
Key claim: A neutrophil-membrane-cloaked ROS-responsive nano-senotherapy co-delivering an MPO-inhibitory KYC dimeric prodrug and Navitoclax reversed established experimental atherosclerosis in ApoE mice by both blocking new senescent-cell formation and clearing existing senescent cells in plaques.
Abstract
The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation-driven by continuous generation and apoptotic resistance-perpetuates plaque pathology and obstructs regression. This study addresses the reversal conundrum through a dual-action strategy: blocking new senescent cell formation while enhancing clearance of existing senescent cells. We developed a ROS-responsive dimeric prodrug (KA) from the MPO-inhibitory tripeptide KYC, which co-assembles with the senolytics Navitoclax into a nano-Senotherapy (N@KA). Further cloaked with neutrophil membranes from AS mice, the biomimetic N@KA@NEM precisely targets plaques, responds to local ROS, and orchestrates senescent cell formation and removal. This targeted senotherapeutic intervention demonstrates effective reversal of established experimental AS, offering a potential solution to the field’s most pressing clinical dilemma.
Why this matters
The finding operationalizes a ‘block-and-clear’ senotherapy concept for atherosclerosis, pairing an MPO/ROS-suppressing prodrug with a canonical senolytic (Navitoclax) inside a plaque-homing biomimetic nanocarrier, and reports reversal of established disease in ApoE mice. It illustrates how delivery engineering — not new senolytic chemistry — is where the vascular-senescence thesis is currently gaining traction, while remaining a preclinical demonstration with all the Navitoclax translational liabilities still unresolved.